| NCT04370145 | Tongji Hospital|Shanghai Children´s Hospital | Cholangitis, Secondary Biliary|Treatment Compliance|Antibodies Drug Specific | 2021-05-01 | PHASE4 |
| NCT03136796 | University Hospital Hradec Kralove | Critical Illness | 2017-05-02 | |
| NCT06072248 | King Abdul Aziz Specialist Hospital | ARDS|Septic Shock | 2020-07-02 | PHASE1|PHASE2 |
| NCT00061438 | Pfizer | Pancreatitis, Acute Necrotizing | 2003-02 | PHASE4 |
| NCT07113587 | Karl Landsteiner Insitute for Nephrology and Haemato-Oncology|Karl Landsteiner University of Health Sciences|University of Vienna|Medical University of Cologne | Peritoneal Dialysis-associated Peritonitis|Peritoneal Dialysis (PD)|Pharmacokinetics|Intravenous Administration|Intravenous|Meropenem|Intraperitoneal|Ampicillin|Aztreonam|Ciprofloxacin|Minimum Inhibitory Concentration (MIC) | 2014-04-08 | PHASE2|PHASE3 |
| NCT04154722 | Ziauddin University | Typhoid Fever | 2019-06-20 | PHASE4 |
| NCT03230838 | Merck Sharp & Dohme LLC | Complicated Urinary Tract Infection|Pyelonephritis | 2018-04-26 | PHASE2 |
| NCT01445678 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Complicated Intra-abdominal Infection | 2011-12-23 | PHASE3 |
| NCT02732327 | Forest Laboratories | Neoplasms|Febrile Neutropenia | 2016-05-17 | PHASE2 |
| NCT01429259 | Joseph Kuti|Thrasher Research Fund | Cystic Fibrosis|Pneumonia|Pseudomonas Aeruginosa Infection | 2012-02 | PHASE4 |
| NCT04816968 | Ospedale San Carlo Borromeo|Associazione Oncologica Milanese AmoLaVita ONLUS | Severe Bacterial Infections | 2021-09 | PHASE1 |
| NCT01297842 | Mahidol University | Drug Safety | 2011-05 | PHASE4 |
| NCT01292031 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|European Commission | Ventilator-associated Bacterial Pneumonia | 2012-05 | PHASE3 |
| NCT00579956 | University of Oxford|Mahidol University|Wellcome Trust | Melioidosis | 2007-12 | NA |
| NCT01828892 | Jinling Hospital, China | Low-output External Gastrointestinal Fistula | 2014-03 | NA |
| NCT04402359 | King Abdul Aziz Specialist Hospital | Ventilator Associated Pneumonia | 2018-07-05 | |
| NCT05355350 | Rambam Health Care Campus|The Chaim Sheba Medical Center|Rabin Medical Center|Hadassah Medical Organization | Beta Lactam Resistant Bacterial Infection|Enterobacteriaceae Infections|Bacteremia | 2022-07-01 | PHASE4 |
| NCT02213796 | Sutep Jaruratanasirikul|Prince of Songkla University | Initial Phase of Severe Sepsis and Septic Shock | 2013-01 | PHASE4 |
| NCT06026852 | University Hospital, Ghent|Research Foundation Flanders|Imec | Infections | 2024-09-26 | NA |
| NCT00435305 | University Hospital Tuebingen | Pneumonia|Bacteremia | 2006-11 | |
| NCT05922124 | Rambam Health Care Campus|Monaldi Hospital|Rutgers Robert Wood Johnson Medical School|Pisa University Hospital|Assaf-Harofeh Medical Center|Sheba Medical Center | Carbapenem Resistant Bacterial Infection|Acinetobacter Bacteremia|Acinetobacter Pneumonia | 2024-09-01 | PHASE4 |
| NCT03174795 | Hoffmann-La Roche | Urinary Tract Infections | 2017-07-11 | PHASE1 |
| NCT06184659 | Scandinavian Critical Care Trials Group | Sepsis|Septic Shock | 2025-06-26 | PHASE4 |
| NCT05565222 | Assistance Publique - H?pitaux de Paris | Sepsis|Septic Shock | 2023-03-11 | PHASE3 |
| NCT06293677 | Centre Hospitalier Universitaire Vaudois|Unisanté Centre universitaire de médecine générale et santé publique|FORCE Fondation Recherche sur le Cancer de l´Enfant | Febrile Neutropenia | 2024-03-01 | PHASE4 |
| NCT00153634 | Seattle Children´s Hospital|Cystic Fibrosis Foundation | Cystic Fibrosis|Chronic Bronchitis | 2004-03 | NA |
| NCT05058105 | Qilu Pharmaceutical Co., Ltd. | Healthy | 2020-10-08 | PHASE1 |
| NCT01554124 | PENTA Foundation|Chiesi Farmaceutici S.p.A. | Meningitis | 2013-02 | PHASE1|PHASE2 |
| NCT04238390 | The University of Queensland|Merck Sharp & Dohme LLC | Bacteremia Caused by Gram-Negative Bacteria | 2022-01 | PHASE3 |
| NCT01158937 | Unity Health Toronto|Sunnybrook Health Sciences Centre|University of Toronto | Cystic Fibrosis Pulmonary Exacerbation | 2010-05 | NA |
| NCT00318994 | Pfizer | Pancreatitis | 2002-02 | PHASE4 |
| NCT01633762 | University Hospital, Gentofte, Copenhagen|University of Copenhagen|Steno Diabetes Center Copenhagen|Rigshospitalet, Denmark | Diabetes|Obesity|Osteoporosis|Inflammation | 2012-04 | EARLY_PHASE1 |
| NCT02349841 | TASK Applied Science|Eduardo Mondlane University|GlaxoSmithKline|Barcelona Centre for International Health Research|Research Center Borstel | Pulmonary Tuberculosis | 2014-09 | PHASE2 |
| NCT07096310 | Ain Shams University | Sepsis | 2024-01-01 | PHASE1|PHASE2 |
| NCT00462878 | PETHEMA Foundation | Allogenic Blood Stem Cell Transplantation|Febrile Neutropenia | 2002-11 | |
| NCT04771884 | Shandong University|Children´s Hospital of Chongqing Medical University | Bacterial Meningitis|Augmented Renal Clearance | 2020-10-01 | |
| NCT04629378 | TASK Applied Science | Tuberculosis | 2020-08-17 | PHASE2 |
| NCT03630081 | Wockhardt | Complicated Urinary Tract Infection|Acute Pyelonephritis | 2024-01 | PHASE3 |
| NCT03840148 | Venatorx Pharmaceuticals, Inc. | Urinary Tract Infections|Acute Pyelonephritis | 2019-08-07 | PHASE3 |
| NCT02972255 | Hoffmann-La Roche | Healthy Volunteers | 2016-10-31 | PHASE1 |
| NCT05925309 | Children´s Hospital of Fudan University | Biliary Atresia|Cholangitis|Anti-Bacterial Agents | 2023-07-01 | NA |
| NCT03671967 | Rambam Health Care Campus|Rabin Medical Center|University of Modena and Reggio Emilia|Tel Aviv Medical Center|Meir Medical Center|Soroka University Medical Center|The Chaim Sheba Medical Center|McGill University Health Centre+Research Institute of the McGill University Health Centre|Jewish General Hospital|Canadian Institutes of Health Research (CIHR)|Hadassah Medical Organization | Beta Lactam Resistant Bacterial Infection|Enterobacteriaceae Infections|Bacteremia | 2019-05-01 | PHASE4 |
| NCT02820987 | Centre Hospitalier Universitaire de Besancon | Septic Shock | 2016-09-27 | PHASE3 |
| NCT04478721 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Spanish Network for Research in Infectious Diseases|Spanish Clinical Research Network - SCReN | Bacteremia | 2020-12-15 | PHASE3 |
| NCT06342115 | Beneficência Portuguesa de S?o Paulo|Merck Sharp & Dohme LLC | Febrile Neutropenia | 2025-03-26 | PHASE4 |
| NCT00307099 | National Institute of Allergy and Infectious Diseases (NIAID) | Bacterial Infection | 2006-10 | PHASE3 |
| NCT07327619 | Qilu Pharmaceutical Co., Ltd. | Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia | 2026-01-22 | PHASE3 |
| NCT03344627 | Mahidol University | Sepsis|Septic Shock|Critical Illness|Carbapenem|Pharmacokinetic|Pharmacodynamic|Clinical Outcome|Organ Failure, Multiple|Morality | 2017-11-27 | NA |
| NCT02437045 | The University of Queensland | Bloodstream Infections | 2015-04 | PHASE4 |
| NCT02609646 | Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva | Critical Illness|Infection | 2016-01 | |
| NCT04233996 | Hospital Universitari de Bellvitge|Institut d´Investigació Biomèdica de Bellvitge|Instituto de Salud Carlos III | Febrile Neutropenia | 2019-06-05 | PHASE4 |
| NCT03891433 | Universidad del Norte | Urinary Tract Infections|Enterobacteriaceae Infections|Infection Due to ESBL Bacteria|Carbapenem|Escherichia Coli Infection|Klebsiella Pneumoniae Infection|Clinical Trial|Drug Resistance, Bacterial | 2019-04-01 | PHASE4 |
| NCT03036826 | University Hospital Tuebingen | Acute Kidney Insufficiency|Anti-Infective Agent Toxicity | 2019-06 | |
| NCT07326540 | BioVersys SAS|BioVersys AG | Hospital Acquired Bacterial Pneumonia (HABP)|Ventilator Associated Bacterial Pneumonia (VABP)|Colistin Resistanrt ABC|Acinetobacter Baumannii-calcoaceticus Complex | 2026-03-27 | PHASE3 |
| NCT05204368 | Evopoint Biosciences Inc. | Complicated Urinary Tract Infection Including Acute Pyelonephritis | 2023-03-30 | PHASE3 |
| NCT02615041 | Sutep Jaruratanasirikul|Prince of Songkla University | Ventilator-Associated Pneumonia | 2004-01 | PHASE4 |
| NCT03157388 | University of Aarhus | Alcoholic Hepatitis | 2017-06-01 | NA |
| NCT03217136 | Merck Sharp & Dohme LLC | Complicated Intra-Abdominal Infection | 2018-04-03 | PHASE2 |
| NCT06072222 | King Abdul Aziz Specialist Hospital | ARDS|Septic Shock | 2020-07-02 | PHASE1|PHASE2 |
| NCT04986254 | The University of Queensland|Royal Brisbane and Women´s Hospital|The Alfred|University Hospital, Ghent|Centre Hospitalier Universitaire de N?mes|Chinese University of Hong Kong|University of Malaya|International Islamic University Malaysia|General Hospital of Larissa|Central Hospital, Nancy, France|Hospices Civils de Lyon | Pneumonia | 2019-10-17 | |
| NCT07556107 | Bassett Healthcare|Johns Hopkins University|Patient-Centered Outcomes Research Institute | Infection|Acute Kidney Injury|Sepsis | 2026-06-01 | PHASE4 |
| NCT07113574 | Karl Landsteiner Insitute for Nephrology and Haemato-Oncology|Karl Landsteiner University of Health Sciences|Medical University of Cologne|University Hospital St. Polten|University of Vienna | Peritoneal Dialysis Associated Peritonitis|Peritoneal Dialysis (PD)|Peritoneal Dialysis|Peritoneal Dialysis, Continuous Ambulatory|Meropenem|Aztreonam|Antibacterial Agents|Intraperitoneal Antibiotics|Kidney Failure, Chronic|Anti-Bacterial Agents|Drug Therapy | 2021-08-31 | PHASE2|PHASE3 |
| NCT06198764 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Mental Health Issue | 2023-07-06 | PHASE3 |
| NCT01992198 | Erzhen Chen|RenJi Hospital | Pancreatitis,Acute Necrotizing | 2012-07 | PHASE4 |
| NCT03970265 | Ludwig-Maximilians - University of Munich | Lung Transplantation | 2019-08-15 | |
| NCT00771316 | Merck Sharp & Dohme LLC | Urinary Tract Infections | 2008-12 | PHASE3 |
| NCT04979806 | Wockhardt|Medpace, Inc. | Complicated Urinary Tract Infection|Acute Pyelonephritis | 2022-08-28 | PHASE3 |
| NCT02506686 | Huashan Hospital | Central Nervous System Infections | 2008-09 | PHASE4 |
| NCT03477422 | Venus Remedies Limited | Urinary Tract Infection Complicated|Acute Pyelonephritis | 2014-01-11 | PHASE3 |
| NCT06841731 | Jiangsu HengRui Medicine Co., Ltd. | Hospital-acquired Bacterial Pneumonia (HABP)|Ventilator-associated Bacterial Pneumonia (VABP) | 2025-04-03 | PHASE2 |
| NCT03543436 | Assistance Publique - H?pitaux de Paris|Fondation H?pital Saint-Joseph|French National Network of Clinical Research in Infectious Diseases (RENARCI)|URC-CIC Paris Descartes Necker Cochin | Urinary Tract Infections | 2019-01-04 | PHASE3 |
| NCT00621192 | The Emmes Company, LLC | Necrotizing Enterocolitis|Intra-abdominal Infection | 2008-06 | PHASE1|PHASE2 |
| NCT02840136 | University Ghent|King Baudouin Foundation|Belgische Vereniging voor Strijd tegen Mucoviscidose | Cystic Fibrosis | 2016-02 | NA |
| NCT00752219 | Pfizer | Complicated Intra-abdominal Infections | 2009-03-31 | PHASE2 |
| NCT01110382 | Janssen Research & Development, LLC | Abscess, Intra-Abdominal|Abdominal Abscess|Abdomen, Acute|Abdominal Pain|Appendicitis|Rupture|Infection|Intestinal Perforation|Peritonitis|Ileus | 2010-12 | PHASE3 |
| NCT01551394 | PENTA Foundation|Chiesi Farmaceutici S.p.A. | Sepsis | 2012-09 | PHASE3 |
| NCT07512596 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hospital-acquired Bacterial Pneumonia+Ventilator-associated Bacterial Pneumonia | 2026-04 | PHASE2 |
| NCT05393505 | The University of Hong Kong|Queen Mary Hospital, Hong Kong | Neutropenic Fever | 2022-10-24 | PHASE4 |
| NCT05042271 | Prince of Songkla University | Autoimmune Diseases | 2020-01-01 | |
| NCT02149329 | Amsterdam UMC, location VUmc|ZonMw: The Netherlands Organisation for Health Research and Development|FondsNutsOhra | Febrile Neutropenia|Hematological Malignancy | 2014-12 | PHASE4 |
| NCT03452839 | Università Vita-Salute San Raffaele | Antibiotic Resistant Infection|Critical Illness | 2018-06-05 | PHASE4 |
| NCT04489459 | Al-Azhar University | Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae | 2019-09-21 | PHASE4 |
| NCT00438269 | Canadian Critical Care Trials Group|The Physicians´ Services Incorporated Foundation | Nosocomial Infection|Pneumonia|Systemic Inflammatory Response Syndrome|Critical Illness|Pyrexia | 2003-02 | PHASE2 |
| NCT04132115 | Azienda Sanitaria-Universitaria Integrata di Udine | Therapeutic Drug Monitoring|Subarachnoid Hemorrhage|Intracerebral Hemorrhage | 2019-10-01 | |
| NCT07122596 | Pakistan Navy Station Shifa Hospital | Sepsis|Bacterial Infection | 2024-04-01 | PHASE4 |
| NCT00619710 | Pfizer | Skin Infection|Abscess|Cellulitis | 2001-02 | PHASE3 |
| NCT01499290 | Pfizer|Forest Laboratories | Complicated Intra-Abdominal Infection | 2012-03 | PHASE3 |
| NCT04257838 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Sepsis|Septic Shock | 2020-02-15 | |
| NCT05784844 | Wake Forest University Health Sciences | Febrile Neutropenia | 2024-08 | PHASE4 |
| NCT02784704 | Tetraphase Pharmaceuticals, Inc | Complicated Intra-abdominal Infections|Complicated Appendicitis | 2016-10-13 | PHASE3 |
| NCT01597973 | University of Michigan | Pneumonia|Blood Stream Infection | 2012-10-06 | PHASE3 |
| NCT01944319 | Qingtao Zhou | Lower Respiratory Tract Infection | 2013-07 | PHASE4 |
| NCT02456974 | University Hospital, Ghent|University Hospital, Antwerp|Queen Fabiola Children´s University Hospital (HUDERF+UKZKF) | Pharmacokinetics|Amoxicillin-clavulanate|Piperacillin-tazobactam|Vancomycin|Teicoplanin|Meropenem|Ciprofloxacin|Amikacin | 2012-05 | |
| NCT07445282 | Sheikh Zayed Medical College | Extensively Drug-Resistant Typhoid Fever|Typhoid Fever|Salmonella Typhi Infection | 2025-05-14 | PHASE4 |
| NCT04671589 | Mabaret Al-Asafara Hospitals | Drug Toxicity | 2021-06 | PHASE4 |
| NCT02176122 | The University of Queensland|International Society of Chemotherapy|Australian Society for Antimicrobials|Queensland Clinical Trials & Biostatistics Centre|Australasian Society for Infectious Diseases | Bloodstream Infections | 2014-02 | PHASE4 |
| NCT01808092 | Pfizer | Nosocomial Pneumonia (NP)|Ventilator-associated Pneumonia (VAP) | 2013-04 | PHASE3 |
| NCT03019965 | Coordinación de Investigación en Salud, Mexico|Instituto Mexicano del Seguro Social|Hospital Infantil de Mexico Federico Gomez|Hospital Regional de Alta Especialidad del Bajio | Sepsis | 2017-02-01 | NA |
| NCT00534287 | Kompetenznetz Sepsis|AstraZeneca|Bayer | Severe Sepsis|Septic Shock | 2007-10 | PHASE3 |
| NCT03858387 | Prince of Songkla University | Critical Illness|Bacterial Infections | 2018-09-01 | |
| NCT01455246 | University of Padova | Cirrhosis|Ascites|Nosocomial Spontaneous Bacterial Peritonitis | 2010-10 | PHASE2|PHASE3 |
| NCT05392634 | N.N. Petrov National Medical Research Center of Oncology|The Foundation for Cancer Research Support (RakFond) | Bladder Cancer | 2022-02-02 | PHASE3 |
| NCT01667094 | The Alfred | Cystic Fibrosis | 2012-09 | PHASE4 |
| NCT04876430 | Hospital de Clinicas de Porto Alegre|Conselho Nacional de Desenvolvimento Científico e Tecnológico | Carbapenem-Resistant Enterobacteriaceae Infection|Bloodstream Infection | 2021-05-04 | PHASE2|PHASE3 |
| NCT05896930 | TASK Applied Science | Pulmonary Tuberculosis | 2017-11-09 | PHASE2 |
| NCT01970371 | Achaogen, Inc.|Department of Health and Human Services | Bloodstream Infections (BSI) Due to CRE|Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE|Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE|Complicated Urinary Tract Infection (cUTI) Due to CRE|Acute Pyelonephritis (AP) Due to CRE | 2014-09-16 | PHASE3 |
| NCT03645668 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Sepsis | 2018-01-30 | PHASE4 |
| NCT03717350 | Hellenic Institute for the Study of Sepsis | Sepsis | 2018-10-27 | PHASE2|PHASE3 |
| NCT06739382 | Beni-Suef University|Cairo University | Ventilation Acquired Pneumonia | 2021-01-01 | PHASE3 |
| NCT01726023 | Pfizer | Complicated Intra-abdominal Infection | 2013-01 | PHASE3 |
| NCT03182504 | Hoffmann-La Roche | Gram-negative Bacterial Infections | 2017-06-15 | PHASE1 |
| NCT02788240 | Institute of Liver and Biliary Sciences, India | Acute on Chronic Liver Failure | 2016-05-01 | NA |
| NCT00891423 | Austin Health | Sepsis | 2009-04 | NA |
| NCT06633718 | Qilu Pharmaceutical Co., Ltd. | Intra-abdominal Infections | 2024-10-31 | PHASE3 |
| NCT02463747 | Tel-Aviv Sourasky Medical Center | Fever|Febrile Neutropenia | 2015-06 | PHASE4 |
| NCT05134298 | Karolinska University Hospital | Antibiotic Pharmacokinetics | 2019-11-01 | |
| NCT02212392 | Benazir Bhutto Hospital, Rawalpindi | Acute Pancreatitis | 2013-01 | PHASE1|PHASE2 |
| NCT07314281 | Indus Hospital and Health Network | Enteric Fever | 2025-04-22 | PHASE4 |
| NCT06828848 | Menarini Group | Gram Negative Infections | 2025-02-18 | PHASE2 |
| NCT05426499 | Poznan University of Medical Sciences|University at Buffalo|The Greater Poland Cancer Centre | Population Modeling of Anti-infective Drugs | 2021-10-01 | |
| NCT00318552 | Pfizer | Sepsis | 2002-01 | PHASE4 |
| NCT06426836 | University Hospital, Ghent | Pharmacokinetics|Amoxicillin-clavulanate|Piperacillin-tazobactam|Meropenem|Cefazolin|Teicoplanin|Vancomycin|Ciprofloxacin|Amikacin | 2016-08-19 | NA |
| NCT01044719 | Imperial College London | Cystic Fibrosis | 2010-01 | PHASE4 |
| NCT06527677 | Antabio|Clinical Research Center Kiel GmbH | Renal Impairment | 2024-07-19 | PHASE1 |
| NCT03830333 | Merck Sharp & Dohme LLC | Complicated Intra-abdominal Infections | 2019-03-20 | PHASE3 |
| NCT03485950 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC|National Cancer Institute (NCI) | Other Infectious Diseases | 2018-05-16 | PHASE2 |
| NCT07484633 | Semmelweis University | Infection|Sepsis|NICU|PICU|Beta Lactams | 2026-04 | PHASE4 |
| NCT02486627 | Achaogen, Inc. | Complicated Urinary Tract Infection|Acute Pyelonephritis | 2016-01-11 | PHASE3 |
| NCT03932123 | Shandong University|Tianjin Central Hospital of Gynecology Obstetrics|Shandong Provincial Hospital|Qianfoshan Hospital | Early Onset Neonatal Sepsis | 2019-05-05 | |
| NCT03571711 | Hannover Medical School | Peritonitis Bacterial|Liver Cirrhosis | 2018-06-28 | |
| NCT01570192 | University of Florida | Bacterial Pneumonia | 2010-09 | PHASE2 |
| NCT01381562 | GlaxoSmithKline | Infections, Intestinal | 2011-10-03 | PHASE2 |
| NCT07089186 | Qilu Pharmaceutical Co., Ltd. | Hospital-acquired Bacterial Pneumonia (HABP)|Ventilator-associated Bacterial Pneumonia (VABP)|Complicated Intra-abdominal Infection (cIAI)|Complicated Urinary Tract Infection (cUTI)|Bloodstream Infection (BSI) | 2025-04-12 | PHASE3 |
| NCT04555798 | Mohamed Gaber Allam|King Abdul Aziz Specialist Hospital | Patients With Respiratory Failure and Shocked | 2022-02-01 | PHASE1|PHASE2 |
| NCT06168734 | Venatorx Pharmaceuticals, Inc.|Biomedical Advanced Research and Development Authority | Ventilator-associated Pneumonia|Hospital-acquired Pneumonia | 2025-06 | PHASE3 |
| NCT04983901 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC | Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm | 2021-09-14 | PHASE2 |
| NCT04553367 | King Abdul Aziz Specialist Hospital | ARDS|Septic Shock | 2020-07-02 | PHASE1|PHASE2 |
| NCT05060419 | Qilu Pharmaceutical Co., Ltd. | Complicated Urinary Tract Infection|Acute Pyelonephritis | 2021-10-08 | PHASE2 |
| NCT05105035 | Arrevus Inc.|Arnasi Group | Melioidosis | 2022-06-14 | PHASE2 |
| NCT03140826 | University Hospital Tuebingen|University Hospital of Cologne | Antibiotic Selection Pressure | 2018-01-30 | |
| NCT01147640 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Complicated Intra-abdominal Infection | 2010-06-25 | PHASE2 |
| NCT05905913 | Antabio | Healthy Volunteers | 2023-04-12 | PHASE1 |
| NCT01732250 | Mical Paul|European Commission | Gram-Negative Bacterial Infections | 2013-03 | PHASE4 |
| NCT03032380 | Shionogi | Healthcare-associated Pneumonia (HCAP)|Hospital Acquired Pneumonia (HAP)|Ventilator Associated Pneumonia (VAP) | 2017-10-24 | PHASE3 |
| NCT03507751 | Medical University of Lublin|University of Warmia and Mazury in Olsztyn | Infection|Renal Failure | 2018-04-02 | |
| NCT06818565 | Institute of Liver and Biliary Sciences, India | Acute-On-Chronic Liver Failure | 2025-02-10 | NA |
| NCT07004049 | National University of Singapore|The University of Queensland|European Clinical Research Alliance for Infectious Diseases (ECRAID) | Bloodstream Infection|Ventilator Associated Bacterial Pneumonia|Hospital Acquired Bacterial Pneumonia|Carbapenem Resistant Bacterial Infection|Multidrug Resistance | 2025-04-21 | PHASE4 |
| NCT05226923 | Sumitovant Biopharma, Inc. | Bacterial Infections | 2022-01-12 | PHASE1 |
| NCT05340530 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Infections | 2022-04 | PHASE1 |
| NCT06916156 | Antabio|Clinartis | Pharmacokinetics Study on Healthy Volunteers Adults | 2025-04-28 | PHASE1 |
| NCT02142751 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Spanish Network for Research in Infectious Diseases | Infection Due to ESBL Escherichia Coli | 2014-07 | PHASE3 |
| NCT02475733 | Pfizer | Complicated Intra-abdominal Infections | 2015-08-01 | PHASE2 |
| NCT05102162 | University of Florida|Food and Drug Administration (FDA) | Pneumonia | 2021-12-17 | PHASE4 |
| NCT02070757 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Healthcare-Associated Pneumonia|Ventilator-Associated Pneumonia|Lung Diseases | 2014-09-02 | PHASE3 |